SpyGlass Pharma(NASDAQ) SGP

SpyGlass Pharma, Inc. helps people with chronic eye conditions. Its devices deliver medicine automatically for three years. This removes the need for daily eye drops.

Eye Care Without Drops

• BIM-IOL System: Artificial lens that releases medication to lower eye pressure for three years; designed for use during routine cataract surgery.
• Drug Ring System: Ring-shaped implant that delivers eye medication for three years; used for patients who already have artificial lenses.
• SpyGlass Platform: Proprietary technology used to develop long-acting treatments for various chronic eye conditions.

Tracking Recent Milestones

• Signed a worldwide licensing deal with the University of Colorado in 2020 for drug dispenser patents.
• Raised $50.0 million in Series C-2 private funding in March 2025.
• Secured $77.3 million through a Series D private funding round in May and June 2025.
• Launched two Phase 3 clinical trials in July 2025 to test its lead glaucoma treatment.
• Completed an initial public offering (IPO) in February 2026 with gross proceeds of $172.5 million.

How the Technology Works

The system fits into standard cataract surgery workflows. This allows surgeons to treat glaucoma without specialized training or extra patient appointments.

By the Numbers

• Net loss reached $33.7 million for the six-month period ended June 30, 2026, up 92% year over year.
• Research and development expenses were $19.5 million for the six months ended June 30, 2026, up 46% year over year.
• General and administrative costs hit $17.9 million for the six months ended June 30, 2026, up 436% year over year.
• Cash and short-term investments totaled $234.2 million as of June 30, 2026.
• Accumulated deficit was $138.4 million as of June 30, 2026.

Bottom Line

SpyGlass Pharma has moved from a private startup to a public clinical developer. Its business centers on commercializing long-acting drug delivery systems for chronic eye diseases.